Patent · US Active

Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors

US10639366B2 · kind B2 · utility

8Cited by

41References

16Claims

0Family size

Assignee

Memorial Sloan Kettering Cancer Center · US

Inventors

Liang Deng · New York, US
Stewart Shuman · New York, US
Jedd D. Wolchok · New York, US
Taha Merghoub · New York, US
Peihong Dai · New York, US
Weiyi Wang · Hangzhou City, CN

Key dates

Filing date	Feb 25, 2016
Grant date	May 5, 2020
Priority date	—
Expiry date	Mar 30, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/24134
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.